Neumora’s antidepressant stumbles in first Phase 3 trial readout

A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial — the company’s first late-stage readout. 

The drug, navacaprant, failed to show a meaningful improvement in depression scores compared to placebo, the company reported Thursday. Both the treatment group and the placebo group reported a 12.5-point reduction in their scores. The drug also failed to show a statistically significant improvement on a scoring system measuring participants’ ability to experience pleasure, when compared to placebo.

This is the first of three Phase 3 studies that Neumora has planned for navacaprant. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Neumora’s antidepressant fails to show efficacy in Phase 3 trial

In a disappointing turn of events, Neumora’s highly anticipated antidepressant has stumbled in its first Phase 3 trial readout. The drug, which was expected to provide a new treatment option for patients with major depressive disorder, failed to show significant efficacy compared to placebo.

The results have come as a blow to Neumora, which had high hopes for the drug based on promising earlier stage trials. The company now faces the difficult task of regrouping and determining the next steps for the development of the drug.

Investors and patients alike are left disappointed by the news, as the need for new and effective treatments for depression remains high. Neumora’s setback serves as a reminder of the challenges and uncertainties inherent in drug development, and underscores the importance of continued research and innovation in the field of mental health.

It remains to be seen what the future holds for Neumora’s antidepressant, but for now, the road ahead looks uncertain.

Tags:

• Neumora antidepressant
• Phase 3 trial
• Neumora drug trial results
• Antidepressant medication
• Neumora clinical trial update
• Mental health treatment
• Depression medication
• Pharmaceutical research
• Neumora drug development
• Antidepressant effectiveness

#Neumoras #antidepressant #stumbles #Phase #trial #readout